To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Pyridostigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. Since it is a quaternary amine, it is poorly absorbed in the gut and doesn't cross the blood-brain barrier, except possibly in stressful conditions.
Additional recommended knowledge
Mode of action
In order to understand the mode of action, a quick outline of a synapse is given below. For more information, look up synapse.
Action potentials are conducted along motor nerves to their terminals where they initiate a Ca2+ influx and the release of acetylcholine (ACh). The ACh diffuses across the synaptic cleft and binds to receptors on the post synaptic membrane, causing an influx of Na+ and K+ ions, resulting in depolarisation. If large enough, this depolarisation results in an action potential. In order to prevent constant stimulation once the ACh is released, an enzyme called acetylcholinesterase is present in the endplate membrane close to the receptors on the post synaptic membrane, and quickly hydrolises ACh.
Pyridostigmine is used to treat muscle weakness in people with myasthenia gravis and to combat the effects of curariform drug toxicity. Pyridostigmine bromide has been FDA approved for military use during combat situations as an agent to be given prior to exposure to the nerve agent Soman in order to increase survival (it has been used in particular during the first Gulf War).
Pyridostigmine is now also used to treat orthostatic hypotension.
Pyridostigmine bromide is available under the trade names Mestinon® (Valeant Pharmaceuticals) and Regonol®.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pyridostigmine". A list of authors is available in Wikipedia.|